

REMARKS

Upon entry of the above amendment, claims 1-8 will be pending in this application.

The amendments to the claims do not introduce new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination.

If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 


Gary M. Nath
Registration No. 26,965
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

Date: June 13, 2005
NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005-1503
(202)-775-8383
GMN/SMM\PA.doc

Appendix A

Claim Amendments

1. (Currently amended) A compound of the formula 1,



in which

R1 is hydrogen, methyl or hydroxymethyl,

R2a and R2b are both hydrogen or together denote a bond,

R3 is 1-7C-alkyl,

R4 is 1-7C-alkyl and

R5 is 1-7C-alkyl,

~~and its salts~~ or a salt thereof.

2. (Currently amended) A ~~compounds~~ compound of the formula

1 according to claim 1, in which

R1 is methyl,

R2a and R2b are both hydrogen or together denote a bond,

R3 is 1-7C-alkyl,

R4 is 1-4C-alkyl and

R5 is 1-4C-alkyl,

~~and its salts~~ or a salt thereof.

3. (Currently amended) A ~~compounds~~ compound of the formula 1 according to claim 1, in which

R1 is methyl,

R2a and R2b are both hydrogen or together denote a bond,

R3 is tert-butyl,


R4 is methyl and

R5 is methyl,

~~and its salts~~ or a salt thereof.

4. (Currently amended) A compound of the formula 1 according to claim 1, in which

R2a and R2b are both hydrogen and which is characterized by the formula 1a,



in which

R₁ is hydrogen, methyl or hydroxymethyl,

R₃ is 1-7C-alkyl,


R₄ is 1-7C-alkyl and

R₅ is 1-7C-alkyl,

~~and its salts~~ or a salt thereof.

5. (Currently amended) A compound of the formula 1 according to claim 1, in which

R_{2a} and R_{2b} together denote a bond and which is characterized by the formula 1b,



in which

R₁ is hydrogen, methyl or hydroxymethyl,


R₃ is 1-7C-alkyl,


R₄ is 1-7C-alkyl and

R₅ is 1-7C-alkyl,


~~and its salts~~ or a salt thereof.

6. (Currently amended) A process for the production of a compound of formula 1a according to claim 4,






which comprises reacting a compound of formula 2,



in which R1 has the meaning given in claim 4,


with a compound of formula 3,



in which R3, R4 and R5 have the meanings given in claim 4
to produce an imine intermediate,

and subjecting the ~~resulting~~ imine intermediate to a ring
closure reaction.

7. (Currently amended) A compound of formula 3



in which


R3 is 1-7C-alkyl,

R4 is 1-7C-alkyl and

R5 is 1-7C-alkyl

or a salt thereof.


8. (Currently amended) ~~Use of a compound of formula 1b~~
~~according to claim 5, for the production of~~ A process of
preparing a compound of formula 4



in which

R1 is hydrogen, methyl or hydroxymethyl,

comprising hydrolyzing by hydrolysis of the compound of
formula 1b



in which

R1 is hydrogen, methyl or hydroxymethyl,

R3 is 1-7C-alkyl,

R4 is 1-7C-alkyl and


R5 is 1-7C-alkyl,

or a salt thereof.

Appendix B

Abstract of the Disclosure

Compounds of the formula 1,



in which the substituents have the meanings mentioned in the description are valuable intermediates for preparing active compounds for the prevention and treatment of gastro-intestinal diseases.